Statistical Issues On Objective, Design, And Analysis Of Noninferiority Active-controlled Clinical Trial

In practice, “noninferiority” active-controlled trials have been designed for three different objectives: establishing evidence of efficacy over placebo, preserving a specific percentage of the effect size of the active control, or demonstrating the test treatment is “not much inferior” to the active control. All three objectives can be represented by the same set of statistical hypotheses with the parameters defined differently. The various designs and statistical analysis procedures for active-controlled trials proposed in the literature can be group into two basic types: the historical-controlled trial approach and the cross-study comparison approach. These approaches require some unverifiable constancy assumptions. Under the constancy assumptions, the cross-study comparison uses the estimate effect of active-control treatment as the unbiased estimate of the active/placebo difference in the current noninferiority trial. A normalized Z-statistic is used to test the hypotheses. On the other hand, the historical controlled trial approach uses a conservative confidence limit as if it were a constant to replace the active/placebo difference in the current trial. The two approaches may lead to consistent conclusions only when the constancy assumptions can be supported by a large number of historical studies giving a consistent active-control treatment effect over placebo and that the active-control effect does not change over time. # This paper does not represent the official position of the Food and Drug Administration nor of Aventis Pharmaceuticals Inc.

[1]  S S Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.

[2]  T. Fleming Evaluation of active control trials in AIDS. , 1990, Journal of acquired immune deficiency syndromes.

[3]  J. Mau,et al.  A statistical assessment of clinical equivalence. , 1988, Statistics in medicine.

[4]  L. Fisher,et al.  Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. , 2001, American heart journal.

[5]  J A Lewis,et al.  Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.

[6]  A. Ebbutt,et al.  Practical issues in equivalence trials. , 1998, Statistics in medicine.

[7]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.

[8]  R. Kay Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.

[9]  L. Fisher Active control trials: what about a placebo? A method illustrated with clopidogrel, aspirin and placebo , 1998 .

[10]  J Röhmel,et al.  Therapeutic equivalence investigations: statistical considerations. , 1998, Statistics in medicine.

[11]  William C Blackwelder Showing a treatment is good because it is not bad: when does "noninferiority" imply effectiveness? , 2002, Controlled clinical trials.

[12]  E. Holmgren,et al.  Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained. , 1999, Journal of biopharmaceutical statistics.

[13]  B. Wiens,et al.  Choosing an equivalence limit for noninferiority or equivalence studies. , 2002, Controlled clinical trials.

[14]  J P Siegel,et al.  Equivalence and noninferiority trials. , 2000, American heart journal.

[15]  Yi Tsong,et al.  Utility and pitfalls of some statistical methods in active controlled clinical trials. , 2002, Controlled clinical trials.

[16]  T R Fleming,et al.  Treatment evaluation in active control studies. , 1987, Cancer treatment reports.

[17]  Yi Tsong,et al.  Some fundamental issues with non‐inferiority testing in active controlled trials , 2002, Statistics in medicine.

[18]  Donald J. Schuirmann A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[20]  R. Temple,et al.  Problems in interpreting active control equivalence trials. , 1996, Accountability in research.

[21]  T R Fleming,et al.  Design and interpretation of equivalence trials. , 2000, American heart journal.

[22]  David F. Kong,et al.  Statistical Methods for Comparison to Placebo in Active-Control Trials , 2001 .

[23]  Y Tsong,et al.  Group sequential test strategies for superiority and non‐inferiority hypotheses in active controlled clinical trials , 2001, Statistics in medicine.

[24]  R. Simon,et al.  Planning and monitoring of equivalence studies. , 1988, Biometrics.

[25]  Walter W. Hauck,et al.  Some Issues in the Design and Analysis of Equivalence Trials , 1999 .